WASHINGTON, D.C. (November 7, 2020) – Pharmaceutical Research and Manufacturers of America made the following statement on the 2020 election:
“We are committed to working with the new administration and Congress to win the fight against COVID-19 and battle the most critical ongoing health challenges facing the United States and the world. Our nation and the world face an unprecedented public health crisis, and the research-based biopharmaceutical industry is working around the clock to develop therapeutics and vaccines to treat and prevent COVID-19.
“We look forward to working with policymakers and regulators to put COVID-19 behind us, to advance policies that lower patient costs and to sustain and protect a robust innovation ecosystem that makes it possible to develop new medicines.”
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested nearly $1 trillion in the search for new treatments and cures, including an estimated $83 billion in 2019 alone